DE10356112A1 - Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem in den Prostglandinstoffwechsel eingreifendem Wirkstoff - Google Patents

Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem in den Prostglandinstoffwechsel eingreifendem Wirkstoff Download PDF

Info

Publication number
DE10356112A1
DE10356112A1 DE10356112A DE10356112A DE10356112A1 DE 10356112 A1 DE10356112 A1 DE 10356112A1 DE 10356112 A DE10356112 A DE 10356112A DE 10356112 A DE10356112 A DE 10356112A DE 10356112 A1 DE10356112 A1 DE 10356112A1
Authority
DE
Germany
Prior art keywords
ethyl
component
amino
hydroxy
methylethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE10356112A
Other languages
German (de)
English (en)
Inventor
Marion Wienrich
Antje Howitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Priority to DE10356112A priority Critical patent/DE10356112A1/de
Priority to PCT/EP2004/012896 priority patent/WO2005060955A1/de
Priority to JP2006540275A priority patent/JP2007512273A/ja
Priority to EP04797878A priority patent/EP1689382A1/de
Priority to CA002546565A priority patent/CA2546565A1/en
Priority to US10/990,979 priority patent/US20050119239A1/en
Publication of DE10356112A1 publication Critical patent/DE10356112A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE10356112A 2003-11-27 2003-11-27 Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem in den Prostglandinstoffwechsel eingreifendem Wirkstoff Withdrawn DE10356112A1 (de)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DE10356112A DE10356112A1 (de) 2003-11-27 2003-11-27 Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem in den Prostglandinstoffwechsel eingreifendem Wirkstoff
PCT/EP2004/012896 WO2005060955A1 (de) 2003-11-27 2004-11-13 Pharmazeutische zusammensetzung aus einem beta-3-adrenozeptor-agonisten und einem in den prostaglandinstoffwechsel eingreifendem wirkstoff
JP2006540275A JP2007512273A (ja) 2003-11-27 2004-11-13 ベータ−３−アドレノセプター作用薬及びプロスタグランジン代謝に影響を及ぼす活性物質から成る医薬組成物
EP04797878A EP1689382A1 (de) 2003-11-27 2004-11-13 Pharmazeutische zusammensetzung aus einem beta-3-adrenozeptor-agonisten und einem in den prostaglandinstoffwechsel eingreifendem wirkstoff
CA002546565A CA2546565A1 (en) 2003-11-27 2004-11-13 Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and an agent intervening in the prostaglandin metabolism
US10/990,979 US20050119239A1 (en) 2003-11-27 2004-11-17 Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and an active substance which influences prostaglandin metabolism

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10356112A DE10356112A1 (de) 2003-11-27 2003-11-27 Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem in den Prostglandinstoffwechsel eingreifendem Wirkstoff

Publications (1)

Publication Number Publication Date
DE10356112A1 true DE10356112A1 (de) 2005-06-23

Family

ID=34609427

Family Applications (1)

Application Number Title Priority Date Filing Date
DE10356112A Withdrawn DE10356112A1 (de) 2003-11-27 2003-11-27 Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem in den Prostglandinstoffwechsel eingreifendem Wirkstoff

Country Status (6)

Country Link
US (1) US20050119239A1 (enExample)
EP (1) EP1689382A1 (enExample)
JP (1) JP2007512273A (enExample)
CA (1) CA2546565A1 (enExample)
DE (1) DE10356112A1 (enExample)
WO (1) WO2005060955A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006250888A1 (en) * 2005-05-24 2006-11-30 Avesthagen Limited A method for the production of a monoclonal antibody to CD20 for the treatment of B-cell lymphoma
MXPA05008575A (es) * 2005-08-12 2007-02-12 Leopoldo Espinosa Abdala Formulaciones farmaceuticas solidas sublinguales conteniendo meloxicam.
EP1769792A1 (de) * 2005-09-30 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co.KG Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden
EP1974725A4 (en) * 2006-01-10 2012-12-05 Kissei Pharmaceutical PREPARATION WITH DELAYED RELEASE AND METHOD OF MANUFACTURING THEREOF
EP1870102A1 (en) * 2006-06-15 2007-12-26 Alpex Pharma SA Solid forms containing meloxicam with improved taste and process for their preparation
EP1947103A1 (en) 2007-01-22 2008-07-23 4Sc Ag Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments
US20090246273A1 (en) * 2008-03-27 2009-10-01 Al-Ghananeem Abeer M Ketorolac Sublingual Spray for the Treatment of Pain
US20120244221A1 (en) * 2010-07-08 2012-09-27 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US9532959B2 (en) 2010-07-08 2017-01-03 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US20130323288A1 (en) 2010-07-08 2013-12-05 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for bedwetting and method of use thereof
US10010514B2 (en) 2010-07-08 2018-07-03 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US9415048B2 (en) 2010-07-08 2016-08-16 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US20120237574A1 (en) * 2010-07-08 2012-09-20 Wellesley Pharmaceuticals, Llc Delayed-release formulation for reducing the frequency of urination and method of use thereof
US10105330B2 (en) 2012-01-04 2018-10-23 Wellesley Pharmaceuticals, Llc Extended, delayed and immediate release formulation method of manufacturing and use thereof
SG11201500410XA (en) 2012-01-04 2015-04-29 Wellesley Pharmaceuticals Llc Delayed-release formulation for reducing the frequency of urination and method of use thereof
BR112014016661A8 (pt) 2012-01-04 2017-07-04 Wellesley Pharmaceuticals Llc formulação de liberação prolongada para reduzir a frequência de urinação e método de uso da mesma
US10278925B2 (en) 2012-01-04 2019-05-07 Wellesley Pharmaceuticals, Llc Delayed-release formulations, methods of making and use thereof
US10792326B2 (en) 2013-06-28 2020-10-06 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for bedwetting and method of use thereof
US10105328B2 (en) 2014-06-06 2018-10-23 Wellesley Pharmaceuticals, Llc Composition for reducing frequency of urination, method of making and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5043358A (en) * 1986-03-04 1991-08-27 Bristol-Myers Squibb Company Gastroprotective process
US4965065A (en) * 1986-04-29 1990-10-23 Bristol-Myers Squibb Company Gastroprotective process and compositions
US5260333A (en) * 1986-08-08 1993-11-09 Bristol Myers Squibb Company Effect of a combination of a terbutaline, diphenhydramine and ranitidine composition on gastrointestinal injury produced by nonsteroidal anti-inflammatory compositions
EP0321613A1 (en) * 1987-12-18 1989-06-28 Bristol-Myers Company The effect of a combination of a beta-adrenergic agonist and certain histamine H1- and/or H2-receptor blockers on gastrointestinal injury produced by nonsteroidal anti-inflammatory compositions
AU4421697A (en) * 1996-09-19 1998-04-14 American Home Products Corporation Method of treating urinary incontinence
MY126489A (en) * 1998-07-08 2006-10-31 Kissei Pharmaceutical Phenoxyacetic acid derivatives and medicinal compositions containing the same
DE19940944B4 (de) * 1999-08-31 2006-10-12 Grünenthal GmbH Retardierte, orale, pharmazeutische Darreichungsformen
AU2001286557A1 (en) * 2000-08-23 2002-03-04 Merck Frosst Canada And Co. Method of treating or preventing urinary incontinence using prostanoid ep1 receptor antagonists
DE10225315A1 (de) * 2002-06-06 2003-12-24 Gruenenthal Gmbh Wirkstoffsalze und Ester von 1-Dimethylamino-3-(3-methoxy-phenyl)-2-methyl- pentan-3-ol und 3-(3-Dimethylamino-1-ethyl-1-hydroxy-2-methyl- propyl)-phenol
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine

Also Published As

Publication number Publication date
WO2005060955A1 (de) 2005-07-07
CA2546565A1 (en) 2005-07-07
US20050119239A1 (en) 2005-06-02
EP1689382A1 (de) 2006-08-16
JP2007512273A (ja) 2007-05-17

Similar Documents

Publication Publication Date Title
EP1572181B1 (de) Pharmazeutische zusammensetzung aus einem beta-3-adrenozeptor-agonisten und einem serotonin- und/oder norepinephrin-reuptake-inhibitor und deren verwendung zur behandlung von blasenfunktionsstoerungen
DE10356112A1 (de) Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem in den Prostglandinstoffwechsel eingreifendem Wirkstoff
DE60313330T2 (de) Synergistische Zusammensetzungen enthaltend einen alpha-2-delta-Liganden, kombiniert mit einem PDEV-Inhibitor zur Behandlung von Schmerz
EP1682183A2 (de) Pharmazeutische zusammensetzung enthaltend einen beta-3-adrenozeptor-agonisten und einem alpha antagonisten und/oder einen 5-alpha reduktase-hemmer
US20040072851A1 (en) Medicinal compositions for treating lower uropathy
DE10352132A1 (de) Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem Alpha Agonisten
EP1804778A1 (de) Verwendung eines beta-3-agonisten zur behandlung von beschwerden der prostata und des unteren urogenitaltrakts
EP1769792A1 (de) Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden
DE10351271A1 (de) Pharmazeutische Zusammensetzung zur Behandlung der Stressinkontinenz und/oder Mischinkontinenz
DE10059413A1 (de) Verwendung von substituierten 6-Dimethylaminomethyl-1-phenyl-cyclohexanverbindungen zur Therapie der Harninkontinenz
DE10352131A1 (de) Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem Alpha Antagonisten
DE102004050952A1 (de) Pharmazeutische Zusammensetzung zur Behandlung von Beschwerden, die mit krankhaften Veränderungen oder Irritationen der Prostata verbunden sind
DE10104369A1 (de) Verwendung von 2-Amino-(4-hydroxy-2-methansulfonamidophenyl)ethanol zur Behandlung der Harninkontinenz
DE10320084A1 (de) Verwendung von Phenoxyessigsäurederivaten zur Behandlung der hyperaktiven Blase

Legal Events

Date Code Title Description
8139 Disposal/non-payment of the annual fee